THE WOODLANDS, Texas,
June 27, 2011 /PRNewswire/ -- Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company
focused on discovering breakthrough treatments for human disease,
announced today that the company presented clinical data from a
mechanistic study of LX4211, a dual inhibitor of sodium glucose
transporters 1 and 2 (SGLT1 and SGLT2), in patients with type 2
diabetes at the 71st Scientific Sessions of the American Diabetes
Association (ADA) in San Diego,
California. In addition, the company announced that it
has commenced enrollment of patients with type 2 diabetes in its
Phase 2b clinical trial of LX4211.
Data from the mechanistic study demonstrated that a single dose
of LX4211 significantly increased circulating levels of GLP-1
(active and total) and PYY, important regulators of glycemic and
appetite control. For more information on this program or to
download a copy of the poster from the ADA meeting, please visit
www.lexpharma.com.
The Phase 2b trial is a randomized, double-blind, placebo
controlled study of LX4211 in approximately 285 adult patients
(18-75 years) with type 2 diabetes who are not adequately
controlled on metformin monotherapy. Patients will be
administered LX4211 in combination with standard metformin therapy
over 12 weeks. Doses will include 75 mg once daily, 200 mg
once daily, 200 mg twice daily, 400 mg once daily or placebo.
The primary endpoint of the study is the change from baseline
in HbA1c at Week 12. Secondary endpoints will include
percentage of patients achieving HbA1c < 7%, and changes in
fasting plasma glucose, 3-hour glucose tolerance test, weight,
blood pressure, and triglycerides. The study will be
conducted at approximately 50 sites in the United States. For additional
information on this study, please see www.clinicaltrials.gov (ID
NCT01376557).
About LX4211
LX4211 is an orally-delivered small molecule under development
as a potential treatment for diabetes. LX4211 inhibits both
sodium-glucose co-transporter type 1 (SGLT1) and sodium-glucose
co-transporter type 2 (SGLT2). SGLT2 is a transporter
responsible for most of the glucose reabsorption performed by the
kidney. SGLT1 is a transporter responsible for glucose and
galactose absorption in the gastrointestinal tract, and to a lesser
extent than SGLT2, glucose reabsorption in the kidney. For
more information on LX4211, please visit www.lexpharma.com.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently
has four drug candidates in mid-stage development for diabetes,
irritable bowel syndrome, carcinoid syndrome and rheumatoid
arthritis, all of which were discovered by Lexicon's research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking" statements,
including statements relating to Lexicon's clinical development of
LX4211, including characterizations of the results of clinical
trials of LX4211, the mechanism of action of LX4211 and the
potential therapeutic and commercial potential of LX4211.
This press release also contains forward-looking statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's ability
to successfully conduct clinical development of LX4211 and
preclinical and clinical development of its other potential drug
candidates, advance additional candidates into preclinical and
clinical development, obtain necessary regulatory approvals,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying
such important factors is contained under "Risk Factors" in
Lexicon's annual report on Form 10-K for the year ended
December 31, 2010, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.